Pfizer announces record accounts, raises the forecasts on the results of the year thanks to the sale of anti-Covid vaccines and lays the foundation for an upward session on the New York Stock Exchange. The US pharmaceutical company announced that it closed the first quarter with revenues of $ 14.58 billion, up from $ 10.08 billion from last year. The result also beats estimates of $ 13.62 billion. First quarter profits were 4.88 billion dollars, up from $ 3.546 billion in the first quarter of 2020.
Highest revenues in 2021
Pfizer has revised upwards revenue forecasts in 2021 thanks to the increase in sales of the Covid-19 vaccine. The pharmaceutical company estimates revenues of $ 26 billion, up from $ 15 billion previously forecast, from vaccine sales alone. The forecasts are above all the new contracts signed until mid-April, which provide for the delivery of further 1.6 billion doses of vaccine that he developed together with the German BioNTech.
The goal of two billion doses in 2021
The company said it can produce this year 2 billion doses of the vaccine and now it expects total revenues (ie related to all its products) for the whole of 2021 ranging in a range between 70.5 and 72.5 billion dollars. The previous estimate saw revenues of between $ 59.4 and $ 61.4 billion.